Moreover, a recent systematic review with meta-analysis, comprising 261,698 patients, concluded that both anti-TNF-α agents and thiopurines are associated with an increased risk of lymphoma, and the risk associated with combination therapy was significantly higher compared to both unexposed patients and monotherapy (21). The gene discussed is TNF; the disease is lymphoma.